Abstract. Glioma is the most common primary intracranial malignancy in the central nervous system. At present, the most important treatment option is surgical resection of the tumor combined with radiotherapy and chemotherapy. The principle of operation is to remove the tumor to the maximal extent on the basis of preserving brain function. However, prominent invasive and infiltrative proliferation of glioma tumor cells into the surrounding normal tissues frequently reduces the efficacy of treatment. This in turn worsens the prognosis, because the tumor cannot be completely removed, which can readily relapse. Chemotherapeutic agents when applied individually have demonstrated limited efficacy for the treatment of glioma. However, multiple different chemotherapeutic agents can be used in combination with other treatment modalities to improve the efficacy while circumventing systemic toxicity and drug resistance. Therefore, it is pivotal to unravel the inhibitory mechanism mediated by the different chemotherapeutic drugs on glioma cells in preclinical studies. The aim of the present review is to provide a summary for understanding the effects of different chemotherapeutic drugs in glioma, in addition to providing a reference for the preclinical research into novel chemotherapeutic agents for future clinical application.

Contents

1. Introduction
2. Temozolomide
3. Nitrosourea-based chemotherapy
4. Platinum chemotherapy
5. Other chemotherapy agents
6. Advances in clinical application of anti-glioma chemotherapeutics
7. Conclusion

1. Introduction

Glioma is a malignancy that originates from glial cells. According to the World Health Organization (WHO) in 2016, gliomas can be classified into four grades, of which grade I and II are low-grade, whereas grade III and IV are high-grade (1). In 2021, WHO updated the molecular biomarkers of different tumor types, recommended the use of Arabic numerals for scoring, emphasized the importance of grading within tumor types, and brought more benefits and meaningful guidance for clinical practice (2). Glioblastoma (GBM) accounts for ~60% of all high-grade gliomas. High-grade gliomas can be observed in individuals of all ages, but are particularly common in men (3-5). Low-grade gliomas will typically relapse after initial treatment. Following recurrence, low-grade gliomas can transform into high-grade gliomas (6-8). The incidence of glioma accounts for ~40% of all malignancies in the central nervous system tumors, which is highly invasive and infiltrative (9). In addition, it has high recurrence rates and low 5-year survival rates, which poses a serious threat to human health (10). The median survival time of patients with glioma is only 15 months (11), whereas the 5-year survival rate is <10% (12). The etiology and mechanism underlying the pathogenesis of glioma remain unclear, but it has been demonstrated to show complex molecular characteristics, such as increases in chromosomes 7 and 19, loss of chromosomes 10 and 13, amplifications of EGFR and mouse double minute 2 homolog, mutations in PTEN, neurofibromatosis type 1, platelet-derived growth factor receptor α1, isocitrate dehydrogenase 1 and deletion of cyclin dependent kinase inhibitor 2A (13,14). Ionizing radiation exposure is also considered to be one of the causes of glioma (14,15).

At present, the standard treatment option for glioma is surgical resection combined with radiotherapy and chemotherapy (16). However, the long-term therapeutic efficacy is limited, where the main reasons are as follows: i) Due to
the invasiveness of this malignancy, local resection of the tumor only removes the primary tumor but cannot remove the surrounding tissues where the tumor has already invaded (17); ii) the chemotherapeutic agent cannot reach the tumor due to the blood-brain barrier (BBB), which causes systemic toxicity and side effects, reducing the maximum efficacy (18,19); and iii) tumor cells develop internal resistance to the agent (20), thus exerting varying degrees of resistance to different types of chemotherapeutic drugs, minimizing the effect of chemotherapy. Therefore, major obstacles remain before glioma can be completely cured (20). The invasiveness of GBM is caused by the signal pathway of tyrosine kinase receptor (21). Tyrosine kinase inhibitors (TKIs) and signal pathways (PI3K/AKT, Wnt/β-catenin, Hedgehog and NF-xB) serve important roles in the progression of GBM (22-24). TKIs selectively inhibit tumor growth and regulate cell proliferation, migration, apoptosis and angiogenic factors by activating intracellular signal transduction (25). Treatment strategies for glioma includes surgery, radiotherapy, chemotherapy, targeting and immunotherapy (25,26). However, chemotherapy agents when applied individually exert limited therapeutic effects (3). As such, different combinations of chemotherapeutic agents can be applied together to overcome drug resistance and reduce their toxic adverse effects (27). Drug delivery systems, such as nanoparticles, liposomes and polymer micelles can all transport chemotherapeutic drugs through the BBB to improve efficacy and enhance the targeting effects (27,28). Therefore, chemotherapy remains to be a basic component of multimodal therapeutic method for malignant glioma treatment (29).

Postoperative application of chemotherapeutic drugs in patients with glioma serves an important role in preventing postoperative recurrence. Considering the existence of the BBB in the central nervous system, the ideal chemotherapeutic drug should be small in molecular weight, lipophilic, non-protein, and able to spread to the brain stroma through the BBB (30). The main obstacle to effective glioma chemotherapy is currently drug resistance development and the occurrence of toxic side effects. Therefore, there is demand for the development of novel agents and drug delivery systems to alleviate these two challenges for clinical application. A systematic literature search for eligible studies through the electronic search engine PubMed was performed. The keywords for searches were as follows: ‘Glioma’, ‘glioblastoma’ and ‘chemotherapeutic drugs’. Studies published in the past 10 years were searched using these keywords. The prevent review discusses the potential mechanism and application of various chemotherapeutic agents for glioma treatment.

2. Temozolomide

Preclinical study and combination therapy of temozolomide (TMZ). TMZ is a first line chemotherapy drug for glioma (31) and a precursor alkylating agent (32). In addition, TMZ is a small molecule and lipophilic substance that can be taken orally and readily traverses through the BBB (33,34). Data from previous preclinical studies (16,27,35-51) (Table I) showed that it can exert anticancer activity. Wang et al (35) treated C6 cells with TMZ (250-1,000 µM) for 24, 48 and 72 h. The results revealed that TMZ inhibited the proliferation, migration and invasion of C6 cells through the MEK/ERK signaling pathway, and downregulation of vascular endothelial growth factor (VEGF)-C expression to enhance the inhibitory effects of TMZ. The invasive growth and recurrence of gliomas are closely associated with tumor neovascularization. Tumor cells secrete a number of vascular growth factors such as VEGF to facilitate the growth of tumors (52). A previous study by Sonoda et al (53) have revealed that overexpression of VEGF can increase tumor volume and vascular permeability in mice. Effective inhibition of VEGF in gliomas has been previously shown to inhibit neovascularization. Bevacizumab (BEV) is an anti-angiogenic agent, such that treatment with the combination of BEV and TMZ did not weaken the effects exerted by TMZ. Grossman et al (54) revealed that TMZ combined with BEV treatment was able to inhibit VEGF to prolong the survival time of rats injected with U87 cells (109 days). Although TMZ can exert inhibitory effects on glioma cells, it has not been able to significantly improve the survival rate of patients with glioma (36). However, therapy using a combination of different drugs may be effective for gliomas (55). Da Ros et al (36) treated glioma cell lines U87, A172 and T98G with TMZ (100 and 200 µM) in combination with aldoxorubicin, a novel prodrug of doxorubicin (12 µM). The results showed that low concentrations of TMZ (100 µM) conferred no toxicity in any of the cell lines. However, higher concentrations of TMZ (200 µM) were shown to be toxic to U87 and A172 cells whereas T98G cells remained TMZ-resistant (36). Aldoxorubicin could significantly reduce the cell viability of all cell lines tested, where toxicity to T98G cells was shown to be more potent (36). Therefore, it was concluded that the addition of aldoxorubicin can enhance the killing effects of TMZ on TMZ-resistant glioma cells (36). TMZ combined with formononentin has a synergistic inhibitory effect on glioma cells (56). TMZ combined with pilocic and formononentin can inhibit the growth of glioma cells in vitro and tumor growth in vivo (57). In addition, TMZ combined with proteasome inhibitors also have certain antitumor effects. TMZ combined with alaphatinib (EGFR inhibitor) has an inhibitory effect on glioma in vivo and in vitro (58). TMZ combined with bortezomib (BTZ) (proteasome inhibitor) can enhance the sensitivity of TMZ in the treatment of gliomas in vitro and in vivo (59). TMZ combined with amlotinib (a novel multi-target TKI) can synergistically inhibit the proliferation and angiogenesis of glioma cells and inhibit tumor growth in vitro (60). TMZ forms part of the standard chemotherapeutic strategy for the treatment of glioma. However, drug resistance to TMZ and toxic effects (myelosuppression and delayed thrombocytopenia) limit its efficacy, which highlights the importance of exploring the novel treatment options (61,62). Previous preclinical studies (63-65) applied nanoparticles as carriers in an attempt to effectively deliver chemotherapeutic drugs to the glioma region by crossing the BBB, and minimize drug resistance (62). These nanocarriers can be functionalized by some molecules to cross the BBB and specifically target glioma cells. For example, Angiopep2 (A2) has brain-targeting properties, such that its modified polymeric counterpart can penetrate the BBB through receptor-mediated transport, which is widely applied to design nanocarriers (66). Polo-like kinase 1 (PLK1) serves a key role in cell cycle regulation, where its expression in glioma tissues was found to be significantly higher compared...
| Author (year) | Agent | In vivo/In vitro | Combination therapy | Treatment effect                                                                 | (Refs.)|
|--------------|-------|----------------|---------------------|----------------------------------------------------------------------------------|--------|
| Wang et al, 2016 | TMZ | In vitro | - | Inhibiting proliferation, migration and invasion | (35) |
| Da Ros et al, 2018 | TMZ | In vitro | Aldoxorubicin | Enhancing the killing effect of TMZ on TMZ-resistant glioma cells | (36) |
| Shi et al, 2020 | TMZ | Both | Polymer micelle | Inhibiting cell viability and prolonging the survival time of U87 mice | (16) |
| Hu et al, 2021 | TMZ | - | NF-κB and MGMT inhibitors | Downregulating MGMT and improving TMZ sensitivity | (37) |
| Wu et al, 2021 | TMZ | In vitro | Talazoparib | Inhibiting the proliferation and downregulating MGMT and poly (ADP-ribose) polymerase | (38) |
| Rahman et al, 2019 | TMZ | Both | Bortezomib | Inhibiting the proliferation, MGMT, MGMT mRNA and nuclear phosphorylation/activation p65. Prolonging the survival time of mice | (39) |
| Rezaei et al, 2020 | BCNU | In vitro | miR-181a | Inhibiting cell proliferation and migration. Promoting apoptosis | (40) |
| Lu et al, 2016 | Nimustine | In vitro | Hyperbaric oxygen | Inhibiting tumor growth and reducing the tumor volume | (41) |
| Yi et al, 2019 | BCNU | Both | Metal nanoparticles | Inhibiting proliferation and decreasing the survival rate. Targeting efficiency is higher | (42) |
| Ashrafzadeh et al, 2020 | Cisplatin | Both | OX26 monoclonal antibody and liposomes | Increasing the uptake of C6 cells. Improving the mean survival time and reducing toxicity | (43) |
| Zhang et al, 2017 | Cisplatin | In vitro | Nanoparticles and convection-enhanced delivery | The distribution volume of the brain was higher and prolonging the survival time of rats | (44) |
| Thakur et al, 2020 | Doxorubicin | In vitro | Exosomes | Inhibiting the proliferation | (45) |
| Meng et al, 2019 | Doxorubicin | Both | Nano-micelle | Inhibiting the proliferation and inducing apoptosis. Reducing the tumor volume and increasing drug accumulation | (46) |
| Zhang et al, 2017 | Doxorubicin | In vivo | Liposomes and vincristine | Reducing the tumor volume and prolonging the median survival time | (27) |
| Park et al, 2016 | Vincristine | In vitro | - | Inhibiting glioma cell proliferation and glioma angiogenesis | (47) |
| Fu et al, 2019 | Vincristine | Both | Nanoparticles | Increasing the toxic effect of vincristine. Reducing tumor and prolonging the mean survival time | (48) |
| Wu et al, 2016 | Vincristine | Both | Solid nano-lipid particles, NLCS and TMZ | The inhibition effect of NLCS was the strongest and inhibiting tumor growth | (49) |
| Koosha et al, 2017 | Topotecan | In vitro | A966492 and radiation | Decreasing the cell survival rate and increasing the radiation lethal effect | (50) |
| Sharon and Rubinstein, 2021 | Topotecan | In vitro | CaCl2 and PLGA microspheres | Decreasing the relative survival rate of cells and increasing the toxic effect of topotecan | (51) |

TMZ, temozolomide; MGMT, O6-methylguanine-DNA methyltransferase; NLCS, nano-lipid carriers; BCNU, carmustine.
ZHOU et al.: APPLICATION OF DIFFERENT CHEMOTHERAPEUTIC DRUGS IN GLIOMA

Inhibition of PLK1 activity can lead to cell cycle arrest and increase apoptosis of glioma cells. Shi et al. (16) previously prepared a polymer micelle modified by A2 (A2PEC). These micelles in turn encapsulated TMZ and small interfering RNA (siRNA) targeting PLK1 (TMZ-A2PEC/siPLK), which were used in U87 and LN-299 glioma cells. The results of these previous in vitro experiments showed that TMZ-A2PEC/siPLK could effectively reduce cell viability to a greater extent compared with that mediated by TMZ alone. In addition, results from in vivo experiments revealed that TMZ-A2PEC/siPLK could significantly prolong the survival time of mice injected with U87 and LN-299 glioma cells. The degree of weight loss was also the slowest in the TMZ-A2PEC/siPLK, which also exhibited the least systemic toxic effects. TMZ-A2PEC/siPLK is an option for glioma therapy because it can reverse drug resistance while minimizing the toxicity of TMZ (16). This strategy of drug co-delivery using nanocarriers and molecular targeting has the potential of reversing chemotherapeutic drug resistance, reducing toxic effects and improving treatment efficacy.

Study on targeted therapy for reversing TMZ resistance. The unique stability and solubility of TMZ render it viable for oral administration and gives it the ability to pass through the BBB. It can be activated without liver metabolism and can spontaneously transform into the active alkylating agent monomethyl triazine 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MITC) under physiological conditions (67,68). The main mechanism of TMZ for treating glioma is to first deliver its methyl group to tumor cell DNA, causing DNA methylation and DNA damage in tumor cells. This in turn inhibits tumor cell proliferation, while inducing cell apoptosis (62,69). TMZ destroys the DNA of tumor cells by delivering the active methyl groups to O6 and N7 position of guanine and the N3 position of adenine to form cytotoxic O6-methylguanine (O6-MeG), N7-methylguanine (N7-MeG) and N3-methyladenine (N3-MeA) (70). By contrast, cytotoxicity induced by TMZ is mainly caused by O6-MeG. TMZ-resistant DNA repair systems mainly include O6-methylguanine-DNA methyltransferase (MGMT), mismatch repair (MMR) and base excision repair (BER) (Fig. 1) (62).

In the absence of MGMT expression, O6-MeG mismatches with thymine, where MMR removes thymine leaving behind the methylated guanine, which reduces the efficiency of DNA mismatch repair and produces double strand breaks, in turn inducing eventual cell death. BER can repair N7-MeG and N3-MeA so that the tumor cells survive (71,72). In the absence of MGMT expression, O6-MeG mismatches with thymine, where MMR removes thymine leaving behind the methylated guanine, which reduces the efficiency of DNA mismatch repair and produces double strand breaks, in turn inducing eventual cell death. BER can repair N7-MeG and N3-MeA so that the tumor cells survive (71,72). MGMT is the most important factor for TMZ resistance in GBM and can be regulated by various factors, including transcription factors, epigenetic elements (such as methylation, phosphorylation, histone acetylation and microRNA expression from the MGMT promoter), the protein kinase A, and the MAPK/JNK and NF-κB signaling pathways (76). Both O6-benzylguanine (O6-BG) and O6-(4-bromophenyl) guanine (O6-BTG) are MGMT inhibitors. Although both held promise as a treatment option for glioma, they can cause damage to normal tissues,

![Figure 1. DNA repair mechanism of TMZ against tumor resistance. MGMT, O6-methylguanine-DNA methyltransferase; O6-MeG, O6-methylguanine; N7-MeG, N7-methylguanine; N3-MeA, N3-methyladenine; CH₃, methyl; MMR, mismatch repair; BER, base excision repair.](image-url)
Nitrosourea-based chemotherapy

Targeted therapy and other combinatorial therapy using nitrosourea-based chemotherapeutic drugs. Nitrosourea-based chemotherapeutic drugs, including nimustine (ACNU), carmustine (BCNU), lomustine (CCNU) and ranimustine can pass through the BBB. ACNU is a second-line chemotherapeutic agent for the treatment of gliomas (78,79). Nitrosourea-based chemotherapeutic agents act by inducing cytotoxicity in malignant gliomas, where they can induce tumor cell death and changes in biological behavior. These drugs mainly target tumor cell DNA by first alkylating the bases of tumor cell DNA, which then form inter-chain crosslinks. This causes high cytotoxicity, induces DNA double-strand break and prevents DNA replication and transcription to finally result in cell apoptosis and necrosis (80). Nitrosourea chemotherapeutic drugs have myelosuppression and hematological toxicity (80,81). Due to the limited efficacy of chemotherapeutic drugs when applied alone, previous studies that investigated the effects of multiple combination therapies revealed that the resultant efficacy is superior compared with that in chemotherapy alone (30,80,82). O²⁻-alkylguanine-DNA alkyltransferase (AGT)/MGMT is the main component that determines the efficacy and drug resistance of nitrosourea. O²⁻-BG is an inhibitor of AGT that can effectively inhibit the activity of AGT. By contrast, O²⁻-BTG can exert superior inhibitory effects on AGT, and has since entered clinical trial testing, but it lacks a specific target and induces serious myelosuppressive toxicity (83,84). Tumor cell death is dependent on the inhibition of glycolysis. The glycolysis inhibitor 3-bromopyruvate combined with BCNU has been shown to significantly enhance the cytotoxicity of BCNU while reducing intracellular ATP and glutathione levels in human glioma cell lines SF763 and SF126. Glycolysis inhibitors are expected to become an effective agent for reversing nitrosourea resistance (84). Rezaei et al (40) previously treated U373 glioma cells with microRNA (miR or miRNA)-181a combined with BCNU. The results showed that miR-181a mediated downregulation of AKT1, suggesting that miRNA can inhibit glioma cell proliferation by regulating the PI3K/AKT signaling pathway. In addition, miR-181a significantly reduced the semi-inhibitory concentration of BCNU from 169.8 µM in BCNU alone to 83.25 µM in the combined treatment group. The combined use of miR-181a and BCNU was also shown to significantly inhibit cell migration compared with that in BCNU alone. In addition, miR-181a could potentiate apoptosis induced by BCNU (40). Hyperbaric oxygen is a non-invasive form of therapy that can inhibit glioma cell proliferation and inflammatory cell infiltration. Lu et al (41) used hyperbaric oxygen combined with ACNU to treat mice injected with the human glioma SU3 stem cells, which significantly inhibited tumor growth and reduced tumor volume, where the tumor inhibition rate was 76.29%. The tumor weight of the mice treated with combined therapy was found to be significantly lower compared with that in mice treated with either drug alone, suggestive of a synergistic effect. Subsequent tumor histopathological results showed that after hyperbaric oxygen combined with ACNU treatment, the degree of necrosis and inflammatory cell infiltration were reduced. However, toxicity associated with nitrosourea-based chemotherapy and resistance to nitrosourea are key factors that minimize their efficacy. To address the toxicity issue, Yi et al (42) used the synthesized BCNU and loaded them into metal nanoparticles prior to treating glioma U251 cells, which was found to inhibit proliferation while significantly decreasing its survival rate. In the mouse model, this nano-compound was shown to readily deliver the drugs to the brain without causing damage to the normal brain tissue. In addition, it tended to preferentially accumulate in glioma cell masses, to a greater degree.
compared with the accumulation of BCNU alone. The results of subsequent wound healing assays *in vivo* revealed that the synthesis of BCNU and metal nanoparticles is beneficial to wound tissue regeneration and promote wound healing, implicating them to be another potential treatment option (42). Nitrosourea chemotherapeutic drugs have been applied for the treatment of gliomas before the emergence of TMZ (81). Over the past decade, previous studies have shown that nitrosourea chemotherapy can be used for the remedial treatment of TMZ resistance (85).

4. Platinum chemotherapy

Platinum chemotherapeutic agents include cisplatin, carboplatin and oxaliplatin. It has been reported that the exposure of glioma cells to the platinum family of chemotherapeutic drugs can induce tumor cell death. The potential mechanism underlying this effect may be the induction of single-strand or double-strand breaks in the DNA (86). Cisplatin and carboplatin are broad-spectrum agents that cannot be taken orally. Instead, they need to be injected intravenously because they are not soluble in water and are not stable. In addition, they are polar macromolecules, meaning that they cannot pass through the BBB easily (87). This results in low antitumor efficacy, high risks of systemic toxicity and drug resistance. Cisplatin therapy can cause nephrotoxicity and gastrointestinal toxicity, while carboplatin therapy can cause myelosuppression and ototoxicity (88). After carboplatin and cisplatin are injected intravenously, the permeability of BBB to carboplatin and cisplatin is limited, leading to the uneven distribution of these drugs to the tumor area, where the antitumor effect is poor. However, although arterial infusion can greatly increase the accumulation of drugs in the tumor cell masses, it is considered to be highly toxic (89). To improve therapeutic efficacy and reduce systemic toxicity, chemotherapeutic drugs can be packaged into liposomes, peptide/protein conjugates, polymers, polymer micelles and nanoparticles (90). Transferrin receptor (TR) is a potential biological vehicle for drug delivery in the brain. Furthermore, OX26 is a mouse monoclonal antibody that can target TR in rats. Ashrafzadeh et al (43) previously packaged the OX26 monoclonal antibody into the targeted polyethylene glycol cisplatin liposomes (TPL-Cispt). Results from the cell uptake assay *in vitro* showed that TPL-Cispt delivery resulted in significantly higher cell uptake, specifically increasing uptake by C6 cells 1.43-fold. Subsequent results from *in vivo* experiments showed that the mean survival time (MST) of rats treated with TPL-Cispt was 45 days, which represents a 1.7-fold increase. In addition, the toxicity normally induced by cisplatin was shown to be reduced. Therefore, polyethylene glycol liposomes carrying cisplatin was concluded to improve the treatment efficacy of brain tumors with reduced toxicity. However, lipid nanoparticles are typically large in diameter and adhere to the extracellular matrix, meaning that they cannot penetrate brain tumors efficiently. Zhang et al (44) previously manufactured a type of brain-penetrating nanoparticles encapsulating cisplatin and delivered it by convection-enhanced delivery (CED). CED (Fig. 2) is a minimally invasive, locally targeted drug delivery method. Using stereotactic technology, the therapeutic agents in the catheter are directly injected into the tumor around the BBB to achieve the purpose of accurate targeted therapy (91-93). The diffusion rate of brain-penetrating nanoparticles containing cisplatin in healthy rats and rats injected with F98 glioma cells was found to be significantly higher compared with that in rats treated with cisplatin alone (44). In addition, the distribution volume of brain-penetrating nanoparticles containing cisplatin in the brain was found to be 14 times higher compared with that in the cisplatin-alone group. After the brain-penetrating nanoparticles containing cisplatin and cisplatin alone were delivered separately through CED, the distribution volume of brain-penetrating nanoparticles containing cisplatin in the brain was found to be 29 times higher compared with that in the cisplatin-alone group. In terms of survival, the targeted delivery of brain-penetrating nanoparticles of cisplatin using CED can significantly prolong the survival time of rats with superior tolerance (44). In conclusion, although platinum-based chemotherapeutic agents are highly effective especially *in vitro*, the BBB and occurrence of systemic toxicity limit their efficacy in treating glioma, which require optimization using alternative drug delivery systems.

5. Other chemotherapy agents

*Docetaxel* (DOX). DOX is an anthracycline antibiotic chemotherapeutic agent and is one of the most extensively used antitumor drugs (94). Its main mechanism of action is by quickly entering the nuclei of tumor cells and inhibiting the proliferation of tumor cells by binding to DNA and blocking DNA replication (95,96). DOX has been found to inhibit the proliferation of glioma cells. After the glioma cells were treated with 10 and 100 nM of DOX for 7, 10 and 14 days, the cell survival rate was decreased in a dose- and time-dependent manner, which was the lowest at the dosage of 100 nM DOX for 14 days. However, DOX treatment combined with TMZ conferred no synergistic effects (97). DOX cannot pass through the BBB easily, which limits its use in gliomas. However, exosomes can cross the BBB and serve as a potential carrier for the delivery of chemotherapeutic drugs for glioma. Thakur et al (45) previously loaded DOX into exosomes derived from SF7761 glioma stem cells and U251 glioma cells using a microfluidic device, before treating SF7761 and U251 cells with DOX-containing exosomes. The results showed that DOX-containing exosomes can inhibit the proliferation of cells more effectively compared
with that treated with DOX alone. Over the past number of years, to improve the permeability of BBB to chemotherapeutic drugs, studies into novel drug delivery systems have accelerated. Meng et al (46) used a borneol-modified nano-micelle delivery system to encapsulate and deliver DOX. Results from proliferation experiments in vitro showed that borneol-modified DOX nano-micelles inhibited the proliferation and migration of C6 glioma cells while inducing C6 cell apoptosis to a higher degree, where the magnitude of these inhibitory effects was greater compared with those mediated by DOX alone. The results of tumor experiments in vivo revealed that borneol-modified DOX nano-micelles significantly reduced the tumor volume, bleeding and necrosis in mice compared with those treated with DOX alone. There were no clear side effects following measurements of the weight of the mice. In addition, borneol-modified DOX nano-micelles significantly improved the transport efficiency of DOX across the BBB, which was rapidly accumulated in the brain tissues. However, large doses of or long-term use of DOX can cause cardiomyocyte toxicity, ultimately leading to heart failure. To minimize this toxic adverse effect, it has been proposed that DOX liposomes can be used for targeted delivery, where the combination of DOX liposomes with other drugs conferred superior antitumor activity (94,96). Vincristine can mediate cardioprotective effects against DOX-induced cardiomyocyte toxicity and chemical and hypoxic oxidative stress. T7 is a heptapeptide ligand of the transferrin receptor that can bypass the BBB and target glioma directly. T7 is a D-peptide ligand of VEGF receptor 2 overexpressed on angiogenesis, which has exhibited promising homing characteristics towards glioma. Zhang et al (27) previously applied T7- and A7R dipeptide-modified liposomes to co-deliver DOX and vincristine into mouse glioma tumors, which significantly reduced the tumor volume, reduced the tumor proliferation rate and significantly prolonged the median survival time (34 days). Although DOX confers anti-glioma effects, it cannot pass through BBB at its effective therapeutic dose range. Therefore, it is necessary to develop novel drug delivery systems into the brain to improve its efficacy (98,99).

Vincristine. Vincristine is a type of drug that functions by destroying the stability of microtubules and interferes with the metabolism of tumor cells by acting on the tubulin cytoskeleton of tumor cells (100). Therefore, anti-angiogenesis and antitumor activities (47) have been reported. Park et al (47) reported that vincristine can inhibit glioma cell proliferation in a dose-dependent manner while inhibiting glioma angiogenesis under hypoxic conditions, which was proposed to be mediated at least in part by the inhibition of hypoxia-inducible factor-1α (HIF-1α). Vincristine is a microtubule-targeting drug that is also commonly used in gliomas. Microtubule-associated protein 2 (MAP2) is a microtubule-stabilizing protein. Knocking down MAP2 expression can significantly inhibit the migration and survival of glioma cells in vitro, in addition to inducing apoptosis and increasing the sensitivity of glioma cells to vincristine (101). Vincristine has a large molecular weight and therefore cannot pass through the BBB easily, which can cause peripheral neuropathy and systemic toxicity (102). The existence of BBB and the blood-brain tumor barrier (BBTB) render the accurate targeting of chemotherapeutic drugs challenging. Fu et al (48) designed a peptide nanoparticle carrier dual-modified with T7 and reticulin 4 receptor (NGR) based on encapsulated solid lipid nanoparticles from red blood cells (T7/NGR-RBCSLNs) to encapsulate vincristine for the treatment of gliomas. T7 was found to penetrate the BBB and target glioma cells. NGR is a polypeptide ligand of CD13 that is overexpressed during angiogenesis and has demonstrated promising homing characteristics towards glioma. In addition, it can penetrate the BBTB and target glioma cells. The results of cytotoxicity testing in vitro showed that T7/NGR-RBCSLNs encapsulated with vincristine could significantly increase the toxic effects of vincristine on C6 cells. Subsequent tumor experiments in vivo found that the tumor in the T7/NGR-RBCSLNs-encapsulated vincristine group was significantly reduced, where the relative tumor inhibition rate was the highest and the MST was significantly prolonged (36 days). Vincristine combined with the double-targeting delivery (T7/NGR-RBCSLNs) showed the optimal anti-glioma effects in vivo and in vitro in the brain. The efficacy conferred by treatment with only a single chemotherapeutic drug is limited whereas treatment with a combination of drugs can improve efficacy without worsening systemic toxicity. Therefore, overcoming drug resistance using other drug delivery systems is required to enhance the efficacy of chemotherapy. Wu et al (49) used solid nano-lipid particles and nano-lipid carriers (NLCS) to enclose vincristine and TMZ. Subsequent results from the in vitro cytotoxicity assay showed that the inhibitory effect of NLCS-vincristine + TMZ on U87 glioma cells was the most potent, which was significantly higher compared with that mediated by either drug alone. The results of this previous tumor study in vivo showed that NLCS-encapsulated vincristine and TMZ significantly inhibited tumor growth, where the tumor inhibition rate was >80%. These results were consistent both in vivo and in vitro. This dual-drug administration provides a novel idea for the clinical intervention of glioma.

Topotecan. Topotecan is a water-soluble, semisynthetic camptothecin analog that has a small molecular weight and can pass through the BBB (103). It has been approved for use in different types of tumors as topoisomerase I inhibitors by Serwer et al (104). It is toxic to glial cells and relatively nontoxic to normal brain tissue (105). Topotecan can form stable topoisomerase I and DNA cleavage complexes in vivo and in vitro. During the process of DNA replication in tumor cells, topoisomerase I can be embedded in DNA, resulting in DNA damage and fragmentation, which finally promote the death of tumor cells (104). Topotecan has significant reported antitumor effects according to various preclinical studies (106). Small ubiquitin-like modifier (SUMO) modification is a unique form of protein post-translational modification that is key for the maintenance of cell function under stress or adverse conditions. However, blocking SUMO-1-3 binding in glioma cells can inhibit DNA synthesis, proliferation and survival of glioma cells. Topotecan (1 and 10 µM) significantly inhibited SUMO binding in glioma cells, decreased cyclin-dependent kinase 6 and HIF-1α expression and changed the cell cycle and metabolic profile (103). At present, the most important strategy used to treat glioma is to maximize surgical resection combined with radiotherapy and chemotherapy. However, the adverse
| Clinical trials number | Status                        | Agent   | Phase | Combination therapy                  | Research purposes                                      |
|------------------------|-------------------------------|---------|-------|--------------------------------------|--------------------------------------------------------|
| NCT00272870            | Terminated                    | TMZ     | I     | O6 Benzyl guanine                    | Overcoming TMZ resistance and hematologic toxicity      |
| NCT05052957            | Not yet recruiting            | TMZ     | II    | O6 Benzyl guanine                    | Treatment                                              |
| NCT00687765            | Completed                     | TMZ     | I and II | BSI-201 (PARP-1 inhibitor)         | Determining the maximum tolerated dose of BSI-201 and evaluating efficacy |
| NCT03914742            | Recruiting                    | TMZ     | I and II | BGB-290 (PARP inhibitor)            | Treatment                                              |
| NCT03749187            | Recruiting                    | TMZ     | I     | BGB-290 (PARP inhibitor)            | Evaluating the side effects and the optimal dose       |
| NCT00994071            | Completed                     | TMZ     | I     | ABT-888 (PARP inhibitor)            | Treatment                                              |
| NCT01644955            | Completed                     | Carboplatin | I | Convection-enhanced delivery | Treatment and assessing maximum tolerated dose and toxic effects |
| NCT03603379            | Completed                     | Doxorubicin | I | Anti-EGFR-immunoliposomes loaded with doxorubicin (C225-ILs-dox) | Pharmacokinetics |
| NCT00944801            | Completed                     | Doxorubicin | I and II | Pegylated liposomal EGFR(V)-EDV-Dox | Treatment                                              |
| NCT02766699            | Unknown                       | Doxorubicin | I     | convection-enhanced delivery | Assessment of safety, tolerability and immunogenicity Treatment |
| NCT02333513            | Unknown                       | Vincristine | - | convection-enhanced delivery | Assessing safety and tolerability |
| NCT03927274            | Recruiting                    | Topotecan | I     | Gadolinium DTPA and convection-enhanced delivery | Treatment |
| NCT02278510            | Completed                     | Topotecan | I     | Gadolinium and convection-enhanced delivery | Treatment |
| NCT03154996            | Completed                     | Topotecan | I     | Gadolinium and convection-enhanced delivery | Treatment |

PARP, Poly (ADP-ribose) polymerase; TMZ, temozolomide.
effects caused by radiotherapy and chemotherapy are typically severe. Radiosensitization drugs can improve the efficacy of radiotherapy and reduce its side effects. Koosha et al (50) reported the radiosensitization effects of topotecan combined with A966492 on U87 glioma cell spheres. A966492 is a new type of PARP inhibitor, that can cross the BBB. Compared with radiation alone, topotecan combined with A966492 and 6 mV X-ray radiation significantly increased the lethal effects of radiation on U87 glioma cell spheres. Chemotherapeutic drugs can induce systemic toxicity, while local chemotherapy can reduce systemic exposure. Sharon and Rubinstein (51) divided the dose of topotecan into three equal parts and changed it daily during the 72-h incubation with U87 glioma cells to simulate slow and continuous administration. The relative survival rate of cells was significantly decreased, from 35 to 7%. After CaCl₂ was added, the relative survival rate of cells was decreased even further, significantly from 28 to 1.9%. Topotecan mediated synergistic effects with CaCl₂. Co-loading of CaCl₂ into topotecan poly (lactic-co-glycolic acid) microparticles increased the toxic effects of topotecan on U87 cells, where the cell viability decreased from 72 to 27%. Topotecan has not been routinely used in clinical practice due to toxicity and related pharmacokinetic shortcomings. Drug delivery systems, such as poly (lactic-co-glycolic acid) microparticles, are increasingly being used as the blueprint to develop novel cancer treatments, because this technology can regulate the biological distribution and target accumulation of chemotherapeutic drugs, thereby reducing their toxicity.

6. Advances in the clinical application of anti-glioma chemotherapy

In recent years, patients with glioma who received a single chemotherapy regimen are particularly at risk of drug resistance and relapse. In a previous clinical study of 27 patients treated with TMZ combined with cisplatin, the progression-free survival (PFS) was improved (107). In another clinical trial, TMZ combined with bevacizumab was used to treat 30 patients with recurrent GBM, which yielded a median overall survival (OS) of 51 weeks and a PFS of 52% at 6 months, suggesting that this treatment may be effective for patients with recurrent GBM (108). Herrlinger et al (109) previously compared the effects of CCNU combined with TMZ and standard TMZ therapy on the survival time of patients with GBM and MGMT methylation. The results showed that the OS and median survival time in the CCNU + TMZ treatment group were significantly higher compared with those in the standard TMZ group (109). However, in the study performed by Kim et al (110), the efficacy of procarbazine combined with CCNU for the treatment of patients with recurrent GBM and MGMT methylation was not optimistic due to its toxicity. Although the combination of chemotherapeutic drugs together does exert certain curative effects, drug resistance and toxicity limit efficacy. Therefore, additional prospective studies are required to evaluate the efficacy of various combinations of chemotherapeutic drugs for the treatment of gliomas. A number of clinical trials (Table II) that are evaluating the targeted treatment of GBM using chemotherapeutic drugs and other combination therapies can be found in https://clinicaltrials.gov. Amongst these studies, one of them is the evaluation of the combination of O6-BG and TMZ for the treatment of newly diagnosed GBM (ClinicalTrials.gov identifier no. NCT00272870).

7. Conclusion

Glioma is the most common malignancy in the central nervous system with high recurrence rates and poor prognosis. Drug resistance is the main complication obstructing glioma chemotherapy and provides a significant challenge for improving the therapeutic effects. The development of novel agents and the use of drug resistance induction media and molecular signaling pathway inhibitors are some of the methods of overcoming the resistance of glioma to chemotherapeutic drugs. The combined use of drugs and nanoparticles along with other carriers has been reported to reduce drug resistance and toxicity. Therefore, it is of importance to develop novel drug delivery methods for improving drug solubility, prolonging circulation time, enhancing the targeted effects and improving the efficacy of chemotherapeutic drugs for clinical application. As information is being constantly accumulated regarding the physiology of glioma, the comprehensive application of multiple treatment methods for glioma and the treatment mechanism of chemotherapeutic drugs, chemotherapeutic agents serve an increasingly important role for the treatment of glioma.

Acknowledgements

Fig. 1 is drawn on figdraw (www.figdraw.com). The authors thank figdraw (www.figdraw.com) for its technical support for Fig. 1.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 12071075), the Guangdong Medical Research Fund (grant no. A2020278) and Summit Program of Foshan (grant no. 2019C016).

Availability of data and materials

Not applicable.

Authors’ contributions

YSZ wrote the manuscript. YSZ, NC and LCW collected and analyzed data. J BH and WW critically revised the manuscript. YSZ, NC and LCW collected and analyzed data. JBH and WW critically revised the manuscript. All authors read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 131: 1121-1131, 2016.

2. ZHAO M, van Straten D, Reifenberger G, et al: Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype. Oncol Rep 42: 2355-2362, 2019.

3. Liu S, Shi W, Zhao Q, Zheng Z, Liu Z, Meng L, Dong L and Jiang X: Progress and prospect in tumor treating fields treatment of glioblastoma. Biomed Pharmacother 141: 118110, 2021.

4. Velásquez C, Mansouri S, Mora C, Nassiri F, Suppiah S, Martino J, Zadeh G and Fernández-Luna JL: Molecular and clinical insights into the invasive capacity of glioblastoma cells. J Oncol 2019: 1740763, 2019.

5. MUA M, Gopakumar S, Traylor J, Lee S and Rao G: Glioblastoma multiforme: Novel therapeutic targets. Expert Opin Ther Targets 24: 605-614, 2020.

6. Cheng F and Guo D: MET in glioma: Signaling pathways and targeted therapies. J Exp Clin Cancer Res 38: 270, 2019.

7. Desjardins A, Rich IN, Qu JY, Vredenburgh J, Gurrarangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD and Friedman HS: Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci 10: 2645-2668, 2005.

8. Lapointe S, Perry A and Butowski NA: Primary brain tumours in adults. Lancet 392: 432-446, 2018.

9. Zhang Y, Zhai M, Chen Z, Han X, Yu F, Li Z, Xie X, Han C, Yu L, Yang Y and Mei X: Dual-modified liposome codelivery of doxorubicin and vincristine improve targetting and therapeutic efficacy of glioma. Drug Deliv 24: 1045-1055, 2017.

10. D’Angelo M, Castelli V, Benedetti E, Antonosante A, Catanesi M, Domínguez-Benot R, Pitari G, Ippoliti R and Cimini A: Theranostic nanomedicine for malignant gliomas. Front Bioeng Biotechnol 7: 325, 2019.

11. Brandes AA, Bartolotti M, Tosoni A and Franceschi E: Nitrosoureas in the management of malignant gliomas. Curr Neurol Neurosci Rep 16: 13, 2016.

12. Stupp R: Drug development for glioma: Are we repeating the same mistakes? Lancet Oncol 20: 10-12, 2019.

13. Yu Y, Yang L, Han J, Yang A, Chu L, Xi X, Kan R, Sha C and Sun K: Synthesis and characterization of a series of temozolomide esters and its anti-glioma study. J Pharm Sci 110: 3431-3438, 2021.

14. Karachi A, Dastmalchi F, Mitchell DA and Rahman M: Temozolomide for immunomodulation in the treatment of glioblastoma. Neurol Neurosci Rep 16: 1566-1572, 2018.

15. Cao H, Li X, Wang F, Zhang Y, Xiong Y and Yang Q: Psychochemical-mediated glioma targeted treatment: Drug resistance and novel delivery systems. Curr Med Chem 27: 599-629, 2020.

16. Mirabdaly S, Elieh Ali Komi D, Shakiba Y, Moini A and Kiani A: Effects of temozolomide on U87MG glioblastoma cell expression of CXCR4, MMP2, MMP9, VEGF, anti-proliferative cytotoxic and apoptotic properties. Mol Biol Rep 47: 1187-1197, 2020.

17. Wang Y, Gao S, Wang W and Liang J: Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells, Mol Med Rep 14: 830-839, 2016.

18. Liu S, Li X, Gao F, de Groot JF, Koul D and Yung WKA: PARP-Inhibitor and temozolomide combination in a xenograft mice model of glioblastoma. Oncotarget 9: 34935-34944, 2018.

19. Wu YH, Jiao BH, Wang CY and Wu JL: Regulation of temozolo -
mide resistance in glioma cells via the RIP2/NaF-kB/MGMT pathway. CNS Neurosci Th 27: 552-563, 2021.

20. Wu S, Li X, Gao F, de Groot JF, Koal D and Yung WKA: PARP- mediated PAylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol 23: 920-931, 2021.

21. Rahman MA, Gras Navarro A, Brekke J, Engelsen A, Bindesbøll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, et al: Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. Br J Cancer 121: 545-555, 2019.

22. Rezaei T, Hejazi M, Mansoori B, Mohammad M, Amini M, Mosafer J, Rezaei S, Mokhtarzadeh A and Baradaran B: microRNA-181a mediates the chemosensitivity of glioblastoma to temozolomide and regulates cell proliferation, migration, and apoptosis. Eur J Pharmacol 888: 173483, 2020.

23. Lu Z, Ma J, Liu B, Dai C, Xie T, Ma X, Li M, Dong J, Lan Q and Huang Q: Hyperbaric oxygen therapy sensitizes nitrosourea treatment for glioma in mice. Cancer Med 5: 3147-3155, 2016.

24. Yang F, Jie C and Zhai Y: A novel strategy to the formulation of carnustine and biodegradable nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care. Artif Cells Nanomed Biotechnol 47: 2938-2947, 2019.

25. Mokhtarzadeh MS, Akbarzadeh A, Heydarinasab A and Arjmand M: In vivo glioblastoma therapy using targeted liposomal cisplatin. Int J Nanomedicine 15: 7035-7049, 2020.
60. Xu P, Wang H, Pan H, Chen J and Deng C: Anlotinib combined
63. Peng Y, Huang J, Xiao H, Wu T and Shuai X: Codelivery of
62. Ortiz R, Perazzoli G, Cabeza L, Jimenez-Luna C, Luque R,
25. Thomas AA and Rauschkolb PK: Tumor treating fields for
50. Koosha F, Neshasteh-Riz A, Takavar A, Eyvazzadeh N,
44. Zhang  C, Nance  EA, Mastorakos P, Chisholm  J, Berry  S,
52. Kim MM, Umemura Y and Leung D: Bevacizumab and glioblas-
55. Zhang R, Saito R, Shibahara I, Sugiyama S, Kanamori M,
57. Ni Q, Fan Y, Zhang X, Fan H and Li Y: In vitro and in vivo study on
59-65, 2014.
76. Liu Y, Du Z, Xu Z, Jin T, Xu K, Huang M, Wang S, Zheng Y,
75. Ohba S, Yamashiro  K and Hirose  Y: Inhibition of DNA repair
73. Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J
64. Song S, Mao G, Du J and Zhu X: Novel RGD containing, temo-
62. Yang Z, Wei D, Dai X, Stevens MFG, Bradshaw TD, Luo Y and
69. Hotchkiss KM and Sampson JH: Temozolomide treat-
71. Yu W, Zhang L, Wei Q and Shao A: O6-methylguanine-DNA
51. Yu J, Cui L, Gao C, Chu X, Liu Q, Feng Y, Gong W, Yang M, et al: Dual-modified novel biomimetic nano-
carriers improve targeting and therapeutic efficacy in glioma. ACS Appl Mater Interfaces 11: 1841-1854, 2019.
14. Vengoji  R, Macha  MA, Nimmakayala RK, Rachagani  S,
46. Meng L, Chu X, Lv S, Xiao B, Ye M and Zhu X: Vincristine and
temozolomide combination chemotherapy for the treatment of
glioma: A comparison of solid lipid nanoparticles and nano-
structured lipid carriers for dual drugs delivery. Drug Deliv 23: 1190-2702, 2016.
27. Sonoda Y and Tominaga T: Temozolomide reverses doxorubicin
resistance in combination with temozolomide or dianhydrogalactiol over-
comes temozolomide-resistant glioma cells. Cancers (Basel) 13: 2570, 2021.
78. Kaina B and Christmann M: DNA repair in personalized brain
cancer therapy with temozolomide and nitrosoureas. DNA
Repair (Amst) 78: 128-141, 2019.
81. Lombardi G, Farina P, Della Puppa A, Cecchin D, Pambuku A,
82. Rudà R, Touat M and Soffietti R: Is chemotherapy alone an
option as initial treatment for low-grade oligodendrogliomas? Curr Opin Neurol 33: 707-715, 2020.
84. Sun X, Sun G, Huang Y, Zhang S, Tang X, Zhang N, Zhao L,
Zhang R, Pang G, Chu X, Liu Q, Feng Y, Gong W, Yang M, et al: Dual-modified temozolomide and siRNA with polymeric nanocarrier for
effective glioma treatment. Int J Nanomedicine 13: 3467-3480, 2018.
63. Song S, Mao G, Du J and Zhu X: Novel RGD containing, temo-
49. Kim YH, Son HB, Kim YS, Kim NH, Jeong H, Koo SH and
22. Kodi  AA, Bemelmanns  P, Veronese  C, Prados  J and Melguizo C:
Temozolomide: An updated overview of the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer 1876: 88616, 2021.
57-65, 2019.
23. Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J
58. Vengoji  R, Macha  MA, Nimmakayala RK, Rachagani  S,
80. Berte N, Pizé-Staffa A, Pichea N, Wang M, Borgmann K, Kaina B and
Nicolovka T: Targeting homologous recombination by pharmacological inhibitors enhances the killing response of
glioblastoma cells treated with alkylating drugs. Mol Cancer Ther 15: 2665-2678, 2016.
66. Costagliola di Polidoro A, Zambito G, Haeck J, Mezzanotte L,
51. Yu J, Cui L, Gao C, Chu X, Liu Q, Feng Y, Gong W, Yang M, et al: Dual-modified temozolomide
loaded in folate-conjugated magnetic triblock copolymer nanoparticles to improve the therapeutic efficiency of rat brain gliomas. ACS Biomater Sci Eng 5: 6000-6011, 2019.
69. Afzalipur R, Khoee S, Shiri S, Dehghani S and Moosavi N,
67. Yang Z, Wei D, Dai X, Stevens MFG, Bradshaw TD, Luo Y and
62. Yang Z, Wei D, Dai X, Stevens MFG, Bradshaw TD, Luo Y and
54. Koosha F, Neshasteh-Riz A, Takavar A, Eyvazzadeh N,
56. Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M,
52. Kim MM, Umemura Y and Leung D: Bevacizumab and glioblas-
toma: Past, present, and future directions. Cancer J 24: 180-186, 2018.
57. Ni Q, Fan Y, Zhang X, Fan H and Li Y: In vitro and in vivo study on
glioma treatment enhancement by combining temozolomide with
calycosin and formononetin. J Ethnopharmacol 242: 111699, 2019.
53. Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J
69. Afzalipur R, Khoee S, Shiri S, Dehghani S and Moosavi N,
67. Yang Z, Wei D, Dai X, Stevens MFG, Bradshaw TD, Luo Y and
58. Vengoji  R, Macha  MA, Nimmakayala RK, Rachagani  S,
53. Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J
68. Hotchkiss KM and Sampson JH: Temozolomide treat-
51. Yu J, Cui L, Gao C, Chu X, Liu Q, Feng Y, Gong W, Yang M, et al: Dual-modified temozolomide
loaded in folate-conjugated magnetic triblock copolymer nanoparticles to improve the therapeutic efficiency of rat brain gliomas. ACS Biomater Sci Eng 5: 6000-6011, 2019.
69. Afzalipur R, Khoee S, Shiri S, Dehghani S and Moosavi N,
71. Yu W, Zhang L, Wei Q and Shao A: O6-methylguanine-DNA
methyltransferase (MGMT): Challenges and new opportunities in glioma chemotherapy. Front Oncol 9: 1547, 2020.
65. Liang M, Chu X, Xing H, Liu X, Xin X, Chen L, Jin M, Guan Y,
57. Ni Q, Fan Y, Zhang X, Fan H and Li Y: In vitro and in vivo study on
glioma treatment enhancement by combining temozolomide with
calycosin and formononetin. J Ethnopharmacol 242: 111699, 2019.
54. Koosha F, Neshasteh-Riz A, Takavar A, Eyvazzadeh N,
51. Yu J, Cui L, Gao C, Chu X, Liu Q, Feng Y, Gong W, Yang M, et al: Dual-modified temozolomide
loaded in folate-conjugated magnetic triblock copolymer nanoparticles to improve the therapeutic efficiency of rat brain gliomas. ACS Biomater Sci Eng 5: 6000-6011, 2019.
69. Afzalipur R, Khoee S, Shiri S, Dehghani S and Moosavi N,
71. Yu W, Zhang L, Wei Q and Shao A: O6-methylguanine-DNA
methyltransferase (MGMT): Challenges and new opportunities in glioma chemotherapy. Front Oncol 9: 1547, 2020.
65. Liang M, Chu X, Xing H, Liu X, Xin X, Chen L, Jin M, Guan Y,
57. Ni Q, Fan Y, Zhang X, Fan H and Li Y: In vitro and in vivo study on
glioma treatment enhancement by combining temozolomide with
calycosin and formononetin. J Ethnopharmacol 242: 111699, 2019.
54. Koosha F, Neshasteh-Riz A, Takavar A, Eyvazzadeh N,

85. Yamamura S, Takahashi M, Satomi K, Sasaki N, Kobayashi T, Uchida E, Kawauchi D, Nakano T, Fujii T, Narita Y, et al: Convection-enhanced delivery of platinum-based drugs and Lipoplatin(TM) to optimize the concomitant effect with radiotherapy in F98 glioma rat model. Invest New Drugs 33: 555-563, 2015.

86. Rottenberg S, Disler C and Perego P: The rediscovery of platinum-based cancer therapy. Nat Rev Cancer 21: 37-50, 2021.

87. Yang W, Barth RF, Hsu T, Nakakura RJ, Weldon M, Gupta N, Agus L and Greulich JC: Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors. Radiat Oncol 9: 25, 2014.

88. Shi M, Fortin D, Sanche L and Paquette B: Convection-enhanced delivery of platinum-based drugs and Lipoplatin(TM) to optimize the concomitant effect with radiotherapy in F98 glioma rat model. Invest New Drugs 33: 555-563, 2015.

89. Charest G, Sanche L, Fortin D, Mathieu D and Paquette B: Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain. J Neurooncol 115: 365-373, 2013.

90. da Ros M, Iorio AL, Lucchesi M, Stival A, de Martino M and Sandi I: The use of anthracyclines for therapy of CNS tumors. Anticancer Agents Med Chem 15: 721-727, 2015.

91. Nwagwu CD, Immidissetti AV, Jiang MY, Adeagbo O, Adamson DC and Carbonell AM: Convection enhanced delivery in the setting of high-grade gliomas. Pharmaceuticals 13: 561, 2021.

92. Han Y and Park JH: Convection-enhanced delivery of liposomal drugs for the treatment of glioblastoma multiforme. Drug Deliv Transl Res 10: 1876-1887, 2020.

93. El Demerdash N, Kedda J, Ram N, Brehm E and Tyler B: Novel therapeutics for brain tumors: Current practice and future prospects. Expert Opin Drug Deliv 17: 9-21, 2020.

94. Mizuta Y, Tokuda K, Guo J, Zhang S, Narahara S, Kawanou T, Murata M, Yamaura K, Hoka S, Hashizume M and Akahoshi T: Sodium thiosulfate prevents doxorubicin-induced DNA damage and apoptosis in cardiomyocytes in mice. Life Sci 257: 118074, 2021.

95. Du K, Xia Q, Heng H and Feng F: Temozolomide-doxorubicin conjugate as a double intercalating agent and delivery by apoferritin for glioblastoma chemotherapy. ACS Appl Mater Interfaces 12: 4736-4747, 2020.

96. Liu J, Zhang Y, Chen T, Chen H, He H, Jin T, Wang J and Ke Y: Environmentally self-adaptive nanocarriers suppress glioma proliferation and stemness via codeelivery of shCD163 and doxorubicin. ACS Appl Mater Interfaces 12: 34599-34609, 2020.

97. Horescu C, Elena Cloc C, Tuta C, Sevastre AS, Tache DE, Alexandru O, Artene SA, Danou S, Dricu A and Stefana Oana P: The effect of temozolomide in combination with doxorubicin in glioblastoma cells in vitro. J Immunnoassay Immunochrom 41: 1033-1043, 2020.

98. Maksimenko O, treatment of glioblastoma with MGMT promoter (CeTeG/NOA-09): A randomised, open-label, phase 3 trial. Lancet 393: 678-688, 2019.

99. Muniswamy VJ, Raval N, Gondaliya P, Tambe V, Kalia K and Tekade RK: ‘Dendrimer-Cationized-Albumin’ encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin. Int J Pharm 555: 77-99, 2019.

100. Li GZ, Hu YH, Li DY, Zhang Y, Guo HL, Li YM, Chen F and Xu J: Vincristine-induced peripheral neuropathy: A mini-review. Neurotoxicology 81: 161-171, 2020.

101. Yang L, Xu X and Zheng J: Microtubule-associated protein 2 knockdown sensitizes glioma cells to vincristine treatment. Neuroreport 31: 197-204, 2020.

102. De Witt M, Gamble A, Hanson D, Markowitz D, Powell C, Al Dimassi S, Atlas M, Boockvar J, Ruggieri R and Symons M: Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Mol Med 23: 50-56, 2017.

103. Bernard JD, Ye D, Gessler FA, Lee YJ, Peruzzotti-Jametti L, Baumgarten P, Johnson KR, Maric D, Yang W, Kögel D, et al: Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming. Sci Rep 7: 7425, 2017.

104. Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW and James CD: Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol 13: 1288-1295, 2011.

105. Upadhyayula PS, Spinazzi EF, Argenziano MG, Canoll P and Bruce JN: Convection enhanced delivery of topotecan for gliomas: A single-center experience. Pharmacuetics 13: 39, 2020.

106. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I and Bruce JN: Tissue distribution and antitumor activity of topotecan delivered by intracerebral elysis in a rat glioma model. Neurosurgery 47: 1391-1399, 2000.

107. Wang Y, Kong X, Guo Y, Wang R and Ma W: Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. Medicine (Baltimore) 96: e6261, 2017.

108. Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D and Ahmadi MM: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Cancer Chemother Pharmacol 80: 715-721, 2017.

109. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Pau H, Kortmann RD, Krex D, Grauer O, et al: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): A randomised, open-label, phase 3 trial. Lancet 393: 678-688, 2019.

110. Kim SH, Yoo H, Chang JH, Kim CY, Chung DS, Kim SH, Park SH, Lee YS and Yang SH: Procarbazine and CCNU chemotherapy for recurrent glioblastoma with MGMT promoter methylation. J Korean Med Sci 33: e167, 2018.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.